Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Survival outcomes in isolated severe tricuspid regurgitation according to therapeutic modalities: a systematic review and meta-analysis.

Open heart·2025
Same author

Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2.

Journal of the American College of Cardiology·2024
Same author

Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.

The New England journal of medicine·2024
Same author

Sex-related differences in severe native valvular heart disease: the ESC-EORP Valvular Heart Disease II survey.

European heart journal·2024
Same author

Management of Massive Thrombosis of a Tendyne Valve: The Importance of Heart Valve Centers.

JACC. Case reports·2024
Same author

Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials.

European journal of heart failure·2024

関連する実験動画

Updated: May 12, 2026

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing
11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

11.7K

ミトラル弁疾患 - 現在の治療法と将来の課題

Rick A Nishimura1, Alec Vahanian2, Mackram F Eleid1

  • 1Mayo Clinic, Rochester, MN, USA.

Lancet (London, England)
|March 31, 2016
PubMed
まとめ

ミトラ弁の病気の管理は,手術による修復やトランスキャテーターによるミトラ弁修復 (MitraClip) のような先進的なイメージングと治療法によって進化しています. 将来の方向は,トランスキャテーター技術を含む,一次および二次的ミトラル吐のケアを最適化することに焦点を当てています.

科学分野:

  • 心臓病科
  • 心臓外科
  • 介入心臓科

背景:

  • ミトラル弁の病気の診断と管理は急速に進んでいます
  • 改善された画像と病理学的理解により 早期診断と複雑な治療が可能になります
  • プライマリ・ミトラル・リグルジテーションの管理は手術による修復に焦点を当てているが,二次的ミトラル・リグルジテーションはより明確な未来を示している.

研究 の 目的:

  • ミトラル弁疾患の診断と管理の現状と将来の方向性を検討する.
  • 手術とカテーテル経由の介入における進歩を強調する.
  • ミトラルの環状カルシフィケーションの課題と新たな治療法について議論する.

主な方法:

  • 最新の文献と臨床試験の結果のレビュー
  • 既定および新興の治療方法の分析
  • ミトラル弁疾患の評価におけるイメージングの役割についての議論

主要な成果:

  • 手術による修復はプライマリ・ミトラル・リグルジテーションの標準であり,高い成功率が期待されています.
  • トランスキャテーターによるミトラル弁修復 (MitraClip) は,高リスクの患者で有望であり,中等リスクの患者で研究されている.

さらに関連する動画

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.5K

関連する実験動画

Last Updated: May 12, 2026

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing
11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

11.7K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.5K
  • 修復と置換の両方のトランスキャテーターの技術は,特にミトラルの環状カルシフィケーションでは,拡大される見込みです.

    • 結論:

    • 今後5年間は 優化された外科的修復と トランスカテーターによる介入の 拡大が見込まれます
    • 二次性ミトラル吐の管理戦略を明確にするために,さらなる臨床試験が不可欠です.
    • トランスキャテーターのアプローチは,ミトラルの環状カルシフィケーションを含む複雑なミトラル弁疾患の治療に新しい可能性を提供します.